PlasmaGen raises ₹150 crore, valuation crosses ₹1,500 crore
In a significant development in the Indian biotechnology sector, Bengaluru-based PlasmaGen Biosciences has raised ₹150 crore in a funding round led by ViNS Bioproducts. This investment has propelled the company’s valuation to over ₹1,500 crore, cementing its position as a leading player in the industry. With this funding, PlasmaGen has now raised over ₹600 crore to date, demonstrating the confidence of investors in its vision and capabilities.
PlasmaGen Biosciences is a pioneering company in the field of plasma fractionation, a process that involves extracting life-saving therapies from human plasma. The company operates one of India’s five plasma fractionation facilities near Bengaluru, which is equipped with state-of-the-art technology to produce high-quality plasma-derived products. These products are used to treat a range of diseases, including bleeding disorders, immune deficiencies, and critical care conditions.
The funding round was led by ViNS Bioproducts, a renowned biotechnology company with a strong track record of investing in innovative healthcare ventures. PlasmaGen is also backed by other prominent investors, including Eight Roads, FIL Capital, and F-Prime. These investors have been instrumental in supporting the company’s growth and expansion plans, and their continued backing is a testament to the company’s potential.
The Indian biotechnology sector has been witnessing rapid growth in recent years, driven by government initiatives, increasing demand for healthcare services, and a talented pool of scientists and researchers. The sector has attracted significant investments from domestic and international investors, with many companies raising substantial funds to scale up their operations and expand their product portfolios.
PlasmaGen Biosciences is well-positioned to capitalize on this trend, with its cutting-edge plasma fractionation facility and a strong team of scientists and professionals. The company’s products are designed to meet the growing demand for plasma-derived therapies in India and other emerging markets. With its robust manufacturing capabilities and commitment to quality, PlasmaGen is poised to become a leading supplier of plasma-derived products in the region.
The company’s plans for the future are ambitious, with a focus on expanding its product portfolio, enhancing its manufacturing capabilities, and exploring new markets. The funds raised in this round will be used to support these initiatives, including investments in research and development, marketing, and sales.
The success of PlasmaGen Biosciences is a reflection of the growing ecosystem for biotechnology companies in India. The country has a rich pool of scientific talent, a favorable business environment, and a large market for healthcare products. With the government’s support for the sector, including initiatives such as the Biotechnology Industry Research Assistance Council (BIRAC) and the National Biotechnology Regulatory Authority, the future looks bright for Indian biotechnology companies.
In conclusion, the funding raised by PlasmaGen Biosciences is a significant milestone for the company and the Indian biotechnology sector as a whole. With its strong team, cutting-edge technology, and commitment to quality, PlasmaGen is well-positioned to become a leading player in the global biotechnology industry. As the company continues to grow and expand its operations, it is likely to create new opportunities for scientists, researchers, and healthcare professionals in India and beyond.
About PlasmaGen Biosciences
PlasmaGen Biosciences is a Bengaluru-based biotechnology company that specializes in plasma fractionation and the production of plasma-derived products. The company operates one of India’s five plasma fractionation facilities and is backed by prominent investors, including Eight Roads, FIL Capital, and F-Prime.
News Source: https://ascendants.in/funding-feed/plasmagen-biosciences-raises-rs-150-cr/
About the Author
